As one of Chongqing’s landmark original medical breakthroughs, High‑Intensity Focused Ultrasound (HIFU) has won widespread recognition across the global medical community. Supported by abundant SCI clinical research data and long-term real-world clinical verification, Chongqing Haifu Hospital specializes in minimally invasive HIFU therapy, with core expertise in women’s health conditions including uterine fibroids and adenomyosis. Beyond gynecological disorders, our HIFU technology is also clinically available for treating breast cancer, bone tumors, pancreatic cancer and rectal cancer.

Analogous to a high-precision medical magnifying glass, HIFU concentrates focused ultrasound energy precisely on deep-seated internal lesions from outside the human body. It thermally ablates targeted pathological tissue to achieve localized lesion inactivation, delivering entirely non-invasive treatment with no surgical incisions, zero intraoperative blood loss and minimal harm to adjacent healthy tissues.

Three Core Global Accreditations & Authoritative Endorsements

1. Endorsed by Global Clinical Consensus | FIGO Official Guideline Inclusion

HIFU is formally endorsed by the International Federation of Gynecology and Obstetrics (FIGO), marking the first China-originated medical technology incorporated into FIGO’s global clinical guidelines and established as the international gold-standard therapy for uterine fibroids.

Referenced in FIGO 2025 Best Practice Guidance for Fibroid Diagnosis & Treatment｜DOI: 10.1002/ijgo.15781

2. Globally Certified Center of Excellence by FUS Foundation

Chongqing Haifu Hospital is officially accredited as a Center of Excellence by the US-based Focused Ultrasound Foundation (FUSF). We rank among merely 13 elite certified institutions worldwide, partnering with top-tier medical centers including Stanford University and the University of Oxford as global pioneers in non-invasive focused ultrasound surgery.